Brief: Abliva Gets Positive Regulatory Feedback On KL1333 Phase II/III Study Plan

Abliva AB

17/11/2020 08:13

Nov 17 (Reuters) - Abliva AB  ABLI.ST :
    * ABLIVA RECEIVES POSITIVE REGULATORY FEEDBACK FROM UK MHRA
ON
KL1333 PHASE II/III STUDY PLAN
    * FEEDBACK POSITIONS ABLIVA FOR A CLINICAL TRIAL APPROVAL
ALSO IN
UK, OF ITS PIVOTAL CLINICAL PHASE II/III STUDY, PLANNED TO START
IN SECOND HALF OF 2021

Source: https://bit.ly/35HxvQZ
Further company coverage:  ABLI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))